Schaeffer's Top Stock Picks for '25

2 Sleep Apnea Stocks in Focus Today

The FDA approved Eli Lilly's weight-loss drug for sleep apnea

Deputy Editor
Dec 23, 2024 at 10:51 AM
facebook X logo linkedin


Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. LLY is up 1.7% at $480.55 at last glance, while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for sleep apnea, was last seen down 5% at $225.44 after the news. 

On the charts, LLY posted a much-needed rebound last session, marking its second gain in 10 trading days after bouncing off the 320-day moving average. This came amid Novo Nordisk (NVO) stock's plummet after the pharma name's weight-loss drug CagriSema missed expectations of a late-stage study. Eli Lilly stock has been volatile since its late-October bear gap, which it has yet to recover from, up 33.2% since the start of the year. 

RMD is trading at its lowest levels since late August, though the 180-day moving average, which captured its June pullback, lingers below as potential support. The shares are further removing themselves from their Oct. 25 two-year high of $260.49. Year to date, the equity is up 30.9%. 

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?